Intuitive Surgical: Key takeaways from Society of Robotic Surgery investor summit

Research evidence excerpt

Intuitive Surgical: Key takeaways from Society of Robotic Surgery investor summit

Deutsche Bank

Research

Rating Company Date

Sell Intuitive Surgical 23 July 2026

Industry Update

North America

United States

Reuters Bloomberg Exchange Ticker Price at 22 Jul 2026 (USD) 340.69

ISRG.OQ ISRG US NMS ISRG

Price Target 324.00

Health Care

592.85 -

Medical Supplies & Devices 52-week range 340.69

Key takeaways from Society of Robotic

Valuation & Risks Surgery investor summit

Imron Zafar

Ahead of the SRS scientific sessions that kick off Thursday, today the Society held

Research Analyst

its annual investor symposium featuring program updates from senior executives +1-212-250-3676

of several robotic surgery companies as well as KOL panel discussions spanning an

array of hot topics du jour including technology innovation, site of care, AI, and Pito Chickering

remanufactured instruments. This morning’s earlier-than-expected US FDA

+1-917-635-9954

approval of J&J’s Ottava generated considerable buzz, and herein we present key

takeaways from panel discussions with leadership of J&J, Intuitive, Medtronic, and Kieran Ryan

Stryker. Research Analyst

+1-212-250-6879

We also highlight some interesting findings from a large survey of SRS members Ben Shaver

(n=451 surgeons across specialties from around the world) that help inform the Research Associate

outlook for robot-assisted surgeries: technology adoption/procedure growth, +1-212-250-9926

competitive landscape, and structural trends like continued surgical volume

migration to the ASC and expected impact of AI.

SRS physician survey

n On average, robot-assisted surgery penetration is expected to increase

from 33% presently to 48% five years hence on a worldwide basis. This

implies a WW robotic surgery procedure CAGR of +~11% over this